Under the pressure of epidemic, collection, and medical insurance, how can local pharmaceutical companies discover new growth points?

The 21st Century Business Herald reporter Ji Yuanyuan reported that in recent years, with the emergence of local innovative pharmaceutical companies, the competitive pattern of China's medical industry is changing. At the same time, with the normalization of the systemicization of the new medical reform policy, and the influence of external factors such as epidemic conditions, whether it is multinational pharmaceutical companies or local pharmaceutical companies, it is facing the strategic adjustment or transformation and upgrading pressure brought by changes in the environmental changes. Essence

Recently, Fosun Pharmaceuticals in domestic pharmaceutical heads disclosed the operating performance report in the first half of 2022.期内，复星医药实现营业收入213.4亿元，同比增长25.88%；净利润15.47亿元，同比下降37.67%；扣除非经常性损益的净利润18.62亿元，同比增长18.57%；经营活动产生的The net cash flow was 1.820 billion yuan, an increase of 6.66%year -on -year; the basic earnings per share were 0.60 yuan. During the reporting period, the revenue of the regions and other countries outside China was 7.592 billion yuan, accounting for 35.58%of operating income, an increase of 4.92 percentage points year -on -year.

When talking about the performance of the first half of the year, Wu Yifang, chairman of Fosun Pharmaceutical, told reporters from the 21st Century Business Herald that on the one hand, the price reduction caused the performance to cause short -term pressure; It has a relatively negative effect with the equipment. "From the perspective of the overall environment, the pharmaceutical industry will go through a new round of innovation and upgrade in the next few years. We have seen that the capital market is currently valued by the pharmaceutical industry. From the perspective of the relevant performance of the entire pharmaceutical shop company, everyone It is also facing different pressures. The global market has certain uncertainty because of the various situations such as geopolitics. In response to such a major environment, companies also need to stabilize the future strategy. "Wu Yifang said.

IQVIA also analyzes that Chinese pharmaceutical innovation will still face continuous challenges in the next few years. For example, the R & D pipelines are relatively concentrated and the new drugs are still accelerating; from the perspective of China's local innovation soil, the combination of production and research and technology transformation can still be strengthened; as China BIOTECH enters the product commercialization stage, in the capital market, in the capital market, and In terms of product performance and domestic and overseas market competition, Chinese innovation pharmaceutical companies will face comprehensive examinations in the next 3-5 years.

Multi -partial pressure cling to the new growth point

From the disclosed semi -annual reports, it can be found that in the first half of 2022, many local innovative pharmaceutical companies have slowed down and net profit declined significantly year -on -year. In the face of an increasingly complex internal and external environment, how can enterprises grow steadily?

According to Wu Yifang, in response to the current market environment, Fosun Pharmaceutical is also adjusting its strategic layout. In the future, in the direction of market strategy, the main focus of five keywords:

The first is to focus on the line. Beginning at the beginning of this year, the division of the major businesses of Fosun Pharmaceutical's major businesses is divided into six BUs of generic drugs (mature products and manufacturing), innovative drugs, vaccines, medical devices, medical diagnosis, medical and health services;

The second is to adhere to the internationalization of innovation. The development of innovative products is guided by clinical value, emphasizing differentiated investment and focusing on heavy single items. At the same time, it emphasizes the localization of strategic capabilities. On the basis of the overseas stable layout of the United States, Europe, Japan, Africa, India, it is necessary to localize R & D, registration, commercialization, and even manufacturing capabilities to further enhance the international competitiveness of the enterprise.

Third, excellent operations. By reducing costs to increase costs and improve efficiency, long -term sustainable competitiveness is achieved. At the level of excellent operation, the balanced development of research and development, manufacturing, marketing, and investment should be emphasized.

The fourth is reasonable financial leverage. The cash flow and the company's own cash flow that attaches importance to business activities, pay attention to financial risks, political risks, intellectual property risks in the process of global business expansion. Safety.

Fifth, organize talent strategies. For the entire pharmaceutical industry, professional talents have always been scarce resources. In terms of organizational talent strategy, the company must persist in implementing the "4in" strategy as usual (Innovation, INTERNATIONALINATION, Integration, Intelligent Intelligentification).

"At the new business growth point, the company must have a forward -looking layout when operating business to meet the future changes of the entire industry. For example, the strategic measures of collecting and mining have squeezed the gross profit of some of the original generic drugs. The standardized behavior is good for the industry. Seeing such a trend, enterprises should be prepared in advance to seek new business growth points. "Wu Yifang said.

At present, the global trend of the new crown epidemic has not changed, and the new crown prevention and treatment has become a global gold track. In the first half of this year, the new crown therapy drug market has also become the main direction of Fosun Pharmaceutical. In January and March 2022, Fosun Pharmaceuticals received MPP permits to produce and agreed to the global low -income countries to supply Molnupiravir, Molnupiravir and Pfizer's new crown oral medicine (Nirmatrelvir), and Nama. The Ritonavir group, permits the scope of production includes raw medicines and finished medicines. In July, Fosun Pharmaceuticals and Real Biological Establishment Agreement established strategic cooperation on the joint development of the two parties and the exclusive commercialization of Fosun Pharmaceutical Industry Azfding. The fields of cooperation include new crown viruses, AIDS therapy and prevention. Wu Yifang told the 21st Century Economic Herald reporter that Azf has been transported to Hainan, Henan, Xinjiang, Tibet and other places for the first time. As of now, patients have good overall safety and tolerance in medication. As for the overall effectiveness of the drug and the final result of the specific prevention and control, it is also necessary to wait for the real world data verification. "In view of the long -term growth of the new crown related business, there is still uncertainty, so in the long run, the company cannot build growth in these aspects, and there must be other product line layouts to coordinate."

Innovate pharmaceutical companies to deploy international markets

In fact, since the outbreak of the new crown epidemic in 2020, biomedicine has become the hottest industry in the world. However, starting in the second half of 2021, the capital market has changed, and the biomedical sector has begun to fluctuate down. In 2022, under the influence of multiple uncertain factors, the cooling market for biomedical investment and financing has been significantly reduced, and many innovative enterprises have begun to adjust to prepare for "winter".

In particular, in the face of the competitive situation of "internal rolls" in China, many local innovative pharmaceutical companies have begun to target the international market and compete for "going to sea".

IQVIA data predicts that by 2025, tumors and immunity in two major treatment areas worldwide will be expected to grow at a compound annual growth rate of 9%-12%due to the continuous emergence of new therapy and drugs. The tumor field is expected to increase more than 100 new therapies within five years. By 2025, drug expenditure will increase by more than $ 100 billion to more than $ 260 billion.

According to Fosun Pharmaceutical's financial report, as of the end of June 2022, Fosun Pharmaceutical has established a marketing platform in the United States, Africa and Europe and realized direct sales to preparations to the US market. The device business has covered major regions such as China, the United States, and Europe. Fosun diagnosed the new crown nucleic acid testing kit and the new crown antigen testing kit have been sold in more than ten countries. In addition, with the years of domestic industrial accumulation and global channel network, Fosun Pharmaceutical has become a preferred partner of the world's well -known multinational pharmaceutical companies in China. In the first half of 2022, Fosun Pharmaceuticals and Angjin Holdings subsidiaries were the exclusive business of the two innovative drugs in China (exclusive to Hong Kong, Macao and Taiwan) in China (exclusive to Hong Kong, Macao and Taiwan) on the two types of innovative drugs in Balite (Apmis special tablets) and Parsabiv Licensed licenses reached cooperation. At the same time, Fosun Pharmaceutical's two -way permit also helps to maximize the value of self -developed products. Fosun Pharmaceutical Holding subsidiary Fosin Hanlin successively granted multiple product permits to companies such as ORGANON, EUROFARMA, Getz Pharma Partners cover the incremental market.

"Domestic innovative drugs are an inevitable trend. In recent years, the entire domestic drug manufacturing level has completely reached international standards. The level of drug manufacturing in the head enterprise has been leading the world. Innovative research and development has also been quickly caught up. Enterprises have reached the international level, and the clinical plan made by everyone in the country is basically the same. Therefore, in this case, Chinese innovative pharmaceutical enterprises are also inevitable and a value -added. "Wu Yifang pointed out that the current cost of innovation research and development is getting more costly. The higher the return on investment in a single market, if the global market can be rewarded, it is a great benefit for the entire innovative pharmaceutical company. This is also a major direction to enhance the competitiveness of innovative companies.

"Of course, there will be a lot of challenges in the process of going to sea. Previously, the FDA put forward new requirements in the middle of the approval of certain products. Some products were even out of the door. Pay attention to the changes in the FDA standard, communicate and interact with the local regulatory agencies, adhere to clinical value -oriented, and have forward -looking considerations for clinical research and development. "Wu Yifang emphasized.

- END -